Trademark Overview
On Thursday, June 6, 2024, a trademark application was filed for CTX450 with the United States Patent and Trademark Office. The USPTO has given the CTX450 trademark a serial number of 98589124. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, December 26, 2024. This trademark is owned by CRISPR Therapeutics AG. The CTX450 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of liver, neurological, and neurovascular diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of liver, neurological, and neurovascular diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of liver, neurological, and neurovascular diseases or conditions in the field of in vivo gene editing therapy
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
